6857-88-1 Usage
Description
[3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid is a complex organic compound with a unique molecular structure, featuring a dodecahedral carbon framework, two methyl groups, and two oxygen atoms. It belongs to the class of benz[e]indene derivatives and exhibits a chiral center at the 3a position, with specific stereochemistry at the 3a, 5a, 6, 9a, and 9b positions.
Uses
Used in Pharmaceutical Industry:
[3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid is used as an intermediate in the synthesis of heterocyclic steroids and other complex organic compounds. Its unique structure and functional groups make it a valuable building block for the development of novel pharmaceutical agents with potential therapeutic applications.
Used in Chemical Research:
[3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid is also utilized in chemical research for studying the synthesis, reactivity, and properties of complex organic molecules. Its chiral nature and specific stereochemistry provide opportunities for investigating enantioselective reactions and exploring the influence of molecular geometry on chemical behavior.
Used in the Preparation of Heterocyclic Steroids:
Specifically, [3aS-(3aα,5aβ,6β,9aα,9bβ)]-Dodecahydro-3a,6-diMethyl-3,7-dioxo-1H-benz[e]indene-6-propanoic Acid is used in the preparation of heterocyclic steroids such as Finesteride. Its structural features contribute to the formation of the desired heterocyclic steroidal compounds, which have potential applications in various therapeutic areas, including hormone regulation and treatment of certain medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 6857-88-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,8,5 and 7 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 6857-88:
(6*6)+(5*8)+(4*5)+(3*7)+(2*8)+(1*8)=141
141 % 10 = 1
So 6857-88-1 is a valid CAS Registry Number.
6857-88-1Relevant articles and documents
Photochemical reactions. 21. Sensitized photooxygenation of N-methylated 4-aza-5-androsten-3-one and 4-aza-5-androstene steroidal systems
Piniella,Estape,Lupon,et al.
, p. 3011 - 3016 (1987)
-
Shielding effect of ether C-O bond obtained from proton chemical shifts of 4-oxa-5α- and 4-oxa-5β-androstan-17-ones
Yang, Yanyan,Haino, Takeharu,Usui, Shuji,Fukazawa, Yoshimasa
, p. 2325 - 2336 (1996)
4-Oxa-5α- and 4-oxa-5β-androstanones (1 and 2) were synthesized in order to obtained the NMR shielding parameters for the ether C-O bond. The complete NMR assignment of both the proton and carbon atoms for these compounds and substituent-induced shifts (SIS) from the corresponding androstanones (3 and 4) are presented. The comparison of the molecular structure obtained by MM3 calculation with that of X-ray crystallographic analysis disclosed that the former structure is completly superimposable to the latter in both of the compounds 1 and 2. A combination of the electric field effect and the anisotropy of the magnetic susceptibility of the C-O bond can successfully reproduce the observed SIS values for these androstanones.
CYP11B, CYP17, AND/OR CYP21 INHIBITORS
-
Page/Page column 179, (2012/06/30)
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. Formula (Z)
DECAHYDRO-1H-INDENOQUINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 INHIBITORS
-
Page/Page column 42, (2010/05/13)
Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.